Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients
Autor: | Alexander S. Hamil, Linda Vidarsdottir, Oksana Goroshchuk, Steven F. Dowdy, Ann-Charlotte Björklund, Caroline Palm-Apergi, Iryna Kolosenko |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Adolescent medicine.medical_treatment lcsh:Medicine Apoptosis Cell Cycle Proteins Protein Serine-Threonine Kinases Peripheral blood mononuclear cell Article 03 medical and health sciences 0302 clinical medicine Cell Line Tumor Proto-Oncogene Proteins medicine Humans RNA Messenger Child lcsh:Science Protein Kinase Inhibitors B cells B-Lymphocytes Gene knockdown Chemotherapy Acute lymphocytic leukaemia Multidisciplinary business.industry lcsh:R Infant Transfection Precursor Cell Lymphoblastic Leukemia-Lymphoma Cell cycle Gene Expression Regulation Neoplastic 030104 developmental biology medicine.anatomical_structure Cell culture Child Preschool 030220 oncology & carcinogenesis Drug delivery Cancer research Female lcsh:Q Bone marrow business Cell Division Ex vivo |
Zdroj: | Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020) Scientific Reports |
ISSN: | 2045-2322 |
Popis: | B-cell acute lymphoblastic leukemia (B-ALL) accounts for nearly one fifth of all childhood cancers and current challenges in B-ALL treatment include resistance, relapse and late-onset side effects due to the chemotherapy. To overcome these hurdles, novel therapies need to be investigated. One promising target is Polo-like kinase 1 (Plk1), a key regulator of the cell cycle. In this study, the Plk family expression is investigated in primary peripheral blood and bone marrow mononuclear cells from ten pediatric B-ALL patients. For the first time, short interfering RiboNucleic Neutrals (siRNNs) that enter cells without a transfection reagent are used to target Plk1 mRNA in primary cells from pediatric B-ALL patients. Our results show that the expression of Plk1 and Plk4 is significantly higher in pediatric B-ALL patients compared to healthy donors. Moreover, treatment of primary peripheral blood and bone marrow mononuclear cells from pediatric B-ALL patients, cultured ex vivo, with Plk1-targeting siRNNs results in cleavage of Plk1 mRNA. Importantly, the Plk1 knockdown is specific and does not affect other Plk members in contrast to many small molecule Plk1 inhibitors. Thus, Plk1 is a potential therapeutic target in pediatric B-ALL and selective targeting of Plk1 can be achieved by the use of siRNNs. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |